Mepolizumab almost halves exacerbations in patients with severe asthma
The largest study of patients with severe asthma to date, published in the Lancet special issue on respiratory medicine, shows that those treated with the monoclonal antibody mepolizumab experienced an almost 50 percent reduction in severe exacerbations, emergency room visits, and hospitalizations compared with patients given placebo.
"Mepolizumab is potentially an important advance because it seems to be a safe and effective treatment option for patients with eosinophilic asthma that is associated with frequent flare-ups, and may reduce the need for conventional treatment with oral corticosteroids that can have serious side effects including osteoporosis, high blood pressure, and impaired growth in children", explains Ian Pavord from University Hospitals of Leicester NHS in the UK who led the research.
About a third of individuals with severe asthma have eosinophilic asthma in which inflammatory cells called eosinophils cause inflammation of lung airways. Mepolizumab works by blocking the production of eosinophils and has been shown to reduce the frequency of asthma exacerbations and the need for steroids in two small proof-of-concept studies.
In this study, 621 severe asthmatics with signs of eosinophilic inflammation from 81 centres in 13 countries were randomly assigned to either one of three doses of intravenous mepolizumab (75 mg, 250mg, or 750mg) or placebo on a monthly basis for 12 months.
After a year of treatment, the rate of clinically significant exacerbationsdefined as episodes requiring oral corticosteroids, admission or visit to emergency departmentin the mepolizumab groups was around half that of the placebo group (1.24, 1.46, and 1.15 vs 2.40 per patient per year).
Interestingly, the authors point out that although mepolizumab was effective in reducing exacerbations it failed to produce consistent improvements in symptoms or lung function, adding that, "a dissociation between symptoms and risk of exacerbations probably exists in patients with severe asthma and suggests that they represent separate aspects of the disorder that require different management strategies."
Overall, the frequency of serious adverse events was similar across the treatment groups, the most common being headache and nasopharyngitis (inflammation of the nasal passages). Three patients died during the study, but none of the deaths were related to treatment.
In a linked Comment, Simone Hashimoto and Elisabeth Bel from the University of Amsterdam in The Netherlands say, "These effects are very promising, and raise hope for many patients for whom no effective drugs without significant adverse effects are available today."
They add, "The next step will be to assess the steroid-sparing effects of mepolizumab in a large population of patients who are oral corticosteroid-dependent
. It would be ideal if anti-IL-5 treatment not only reduced the number of exacerbations, but also facilitated the tapering of oral corticosteroids, thereby preventing serious steroid-induced side effects."
More information: www.thelancet.com/… 8-X/abstract
Journal reference:
The Lancet
Provided by
Lancet
-
Treatment for mild asthma leads to improved lung function
Mar 10, 2008 |
not rated yet |
0
-
Risk factors for an exacerbation-prone asthma phenotype
May 20, 2012 |
not rated yet |
0
-
Internet monitoring strategy for severe asthma patients shown to be effective
May 17, 2010 |
not rated yet |
0
-
Asthma exacerbation and large doses of inhaled corticosteroids
Oct 06, 2010 |
not rated yet |
0
-
New treatment reduces severity of asthma attacks in preschoolers
Jan 22, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Solvability of a circuit
3 hours ago
-
Question about perception of colors around light sources
7 hours ago
-
Does a charged particle rotate when traveling through a static Bf?
9 hours ago
-
Find a link between physics and assignment problems
10 hours ago
-
Light as a source of electricity
10 hours ago
-
A question about the energy stored in a capacitor.
10 hours ago
- More from Physics Forums - Classical Physics
More news stories
Stem-cell-based strategy boosts immune system in mice
Raising hopes for cell-based therapies, UC San Francisco researchers have created the first functioning human thymus tissue from embryonic stem cells in the laboratory. The researchers showed that, in mice, ...
Immunology
May 16, 2013 |
4.8 / 5 (5) |
0
|
Resistance to visceral leishmaniasis: New mechanisms involved
Researchers from CNRS, Université Toulouse III - Paul Sabatier and IRD have elucidated new molecular mechanisms involved in resistance to visceral leishmaniasis, a serious parasitic infection. They have shown that dectin-1 ...
Immunology
May 16, 2013 |
not rated yet |
0
Women's immune systems remain younger for longer
Women's immune systems age more slowly than men's, suggests research in BioMed Central's open access journal Immunity & Ageing. The slower decline in a woman's immune system may contribute to women living longer than men. ...
Immunology
May 14, 2013 |
not rated yet |
0
Newly described type of immune cell and T cells share similar path to maturity, according to new study
(Medical Xpress)—Labs around the world, and a core group at Penn, have been studying recently described populations of immune cells called innate lymphoid cells (ILCs). Some researchers liken them to foot soldiers that ...
Immunology
May 14, 2013 |
5 / 5 (3) |
0
|
Not all cytokine-producing cells start out the same way, study finds
(Medical Xpress)—Cytokines are molecules produced by immune cells that induce the migration of other cells to sites of infection or injury, promote the production of anti-microbial agents, and signal the production of inflammatory ...
Immunology
May 13, 2013 |
5 / 5 (1) |
0
|
Researchers identify a potential new risk for sleep apnea: Asthma
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
Computational tool translates complex data into simplified 2-dimensional images
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
New theory on genesis of osteoarthritis comes with successful therapy in mice
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
Ginger compounds may be effective in treating asthma symptoms
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...